Motley Fool Asset Management LLC Sells 6,567 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Motley Fool Asset Management LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 71.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,603 shares of the biopharmaceutical company’s stock after selling 6,567 shares during the period. Motley Fool Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $642,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. SCS Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $50,773,000. Silvant Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $5,456,000. WINTON GROUP Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $2,372,000. Finally, Wealthfront Advisers LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $2,876,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $174.00 on Friday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $172.31 and a twelve month high of $479.79. The stock’s 50 day moving average is $237.78 and its 200-day moving average is $287.22. The firm has a market capitalization of $23.28 billion, a price-to-earnings ratio of 32.34 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period last year, the business earned $2.90 EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. Sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ALNY. Zacks Research lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Wells Fargo & Company decreased their price target on shares of Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 14th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Cantor Fitzgerald reiterated a “neutral” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 30th. Finally, Chardan Capital reissued a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $355.10.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Alnylam reported third-quarter revenue of approximately $1.46 billion, up about 17% year over year and above expectations. Adjusted earnings also exceeded consensus, while the company maintained its fiscal 2026 outlook for product sales. Alnylam Reports 17% Q3 Revenue Growth
• Positive Sentiment: Management expects 2026 TTR franchise sales of roughly $4.2 billion to $4.5 billion, supported by continued demand for Amvuttra. The company also cited positive conviction in nucresiran and continued progress across its RNAi pipeline. Alnylam TTR Sales and TRITON-CM Update
• Neutral Sentiment: The $16.26 reported EPS beat was unusually large because of an approximately $1.9 billion tax benefit, making the headline result less indicative of recurring operating performance. Alnylam Q3 Tax Windfall
• Negative Sentiment: U.S. sales growth for Amvuttra and Onpattro reportedly slowed, raising concerns about the pace of the company’s core TTR franchise despite the maintained outlook. Alnylam Sales Growth Slows
• Negative Sentiment: Alnylam expanded the TRITON-CM heart-disease study for nucresiran to about 2,250 patients while retaining an expected launch around 2030. The larger trial may strengthen evidence, but it increases development demands and reinforces the long wait before a potential revenue contribution. Alnylam Nucresiran Trial Expansion
• Negative Sentiment: Stifel downgraded ALNY to Hold with a $225 price target, while Needham cut its target to $243 from $357, citing a less favorable risk-reward profile. Analysts also flagged potential policy and pricing risks. Stifel Downgrades Alnylam

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.